News | Prostate Cancer | December 22, 2016

Phase II for Development of PSMA-targeted Radionuclide Therapy for Prostate Cancer

Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer

 

prostate, CT scan, Dave Fornell medical

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique radiotherapeutic drug, CTT1403, that targets Prostate-Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate cancer and expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s unique phosphoramidate-based agents, bind irreversibly to PSMA and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells leading to increased accumulation of the therapeutic payload and improved efficacy.

In the Phase I $300K portion of the contract, conducted earlier in 2016, CTT successfully synthesized, tested and identified its lead drug, CTT1403. In addition to the PSMA targeting core, CTT1403 incorporates a chemical motif to increase circulation time, increase tumor uptake and decrease any binding to normal tissues. CTT1403, labeled with lutetium-177, demonstrated excellent circulation times in animal studies and cured 75% of mice implanted with human prostate tumors. CTT is working with Carolyn Anderson, M.D., professor of medicine, at University of Pittsburgh, to evaluate CTT1403 in mouse models of prostate cancer.

Anderson commented: "We are excited to continue our collaboration with CTT. The data from the first phase of the contract are promising, and we look forward to furthering this investigation to translate CTT1403 into human studies.”

The Phase II $2M portion advances CTT1403 into Investigational New Drug (IND) enabling studies, including manufacturing, additional pharmacology and safety assessments. These IND studies will support the initial clinical trial in metastatic prostate cancer. CTT’s strategic plan to identify, target, treat and monitor metastatic prostate cancer, employs CTT1403 as a companion therapeutic agent to CTT’s diagnostic Positron Emission Tomography (PET) agent, CTT1057, that commenced clinical trials in November 2016 to image metastatic sites in patients with prostate cancer.

“We have rationally designed CTT1403 to maximize tumor uptake, while minimizing side effects, and the drug is demonstrating exceptional targeting to prostate tumors in animal models,” stated Beatrice Langton-Webster, Ph.D., CEO of CTT and Principal Investigator on the contract. “We were very excited to see substantial increases in survival times in mice implanted with human prostate tumors. CTT1403 holds great promise as a treatment that will result in meaningful increases in life expectancy for men suffering from prostate cancer.”

For more information: www.cancertargetedtechnology.com/

Related Content

Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Feature | Radiation Oncology | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 20 pieces of radiation oncology content on the Imaging Technology News (ITN) websit